BBI Showcases End to End IVD Assay Development Solution at MEDICA -- MEDICA - World Forum for Medicine


BBI Enzymes Ltd.

BBI Showcases End to End IVD Assay Development Solution at MEDICA

The BBI Group is inviting customers to join them on a journey at this year’s Medica trade fair. The Group, which will be represented by BBInternational, BBI Enzymes and SCIPAC will showcase their combined solution for IVD assay manufacturers.

The solution, which offers an end to end IVD assay development service from initial concept through launch, pulls together the individual areas of expertise of the three companies;

Sourcing Reagents: Biologicals including antigens, antibodies and enzymes; nanoparticle labels and controls and positive samples
Development and Optimisation: Lateral flow test development, custom mobile reader development and patent access
Manufacture and Validation: Contract manufacture and machinery

MEDICA 2011 will be the first time the three sister companies come together following the acquisition of BBI Enzymes in 2007 and more recently SCIPAC in 2010.

Penny McCormick, Head of Group Marketing commented “BBI has executed a strategic acquisition and internal development plan to bring together the core elements of assay development, and we can now truly offer an end to end scale for partners looking for a part or full service. Bringing our 3 reagent companies together allows us to offer the most flexible and all encompassing service ever for BBI – an achievement we are proud of to mark our 25th year in the business.”

MEDICA 2011 takes place in Dusseldorf between the 16th and 19th of November. Visitors to the trade fair will be able to find BBI Enzymes, BBInternational and SCIPAC in Hall 1, booth F24.